SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-134840
Filing Date
2024-05-09
Accepted
2024-05-09 09:01:04
Documents
15
Period of Report
2024-05-09
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d675282d8k.htm   iXBRL 8-K 34695
2 EX-99.1 d675282dex991.htm EX-99.1 22691
6 GRAPHIC g675282g0509054928008.jpg GRAPHIC 3644
  Complete submission text file 0001193125-24-134840.txt   192706

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20240509.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240509_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240509_pre.xml EX-101.PRE 10830
19 EXTRACTED XBRL INSTANCE DOCUMENT d675282d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 24928857
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)